uniQure CEO Soland resigns

14:27 EDT 22 Sep 2016 | BioCentury

Gene therapy company uniQure N.V. (NASDAQ:QURE) said CEO Daniel Soland resigned "due solely to personal family reasons." CFO Matthew Kapusta will be interim CEO, and will remain CFO. uniQure said it will not yet start a search for a permanent CEO while it adjusts its corporate strategy.

uniQure named Soland to the post in December 2015. uniQure shed $0.14 to $7.61 on Thursday. It announced the news after market close.

Original Article: uniQure CEO Soland resigns


More From BioPortfolio on "uniQure CEO Soland resigns"

Quick Search

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...